Type 2 Diabetes Mellitus

Complex MONDO:0005148 Pathograph 9 Metabolic Disease Endocrine Disease

Ask OpenScientist

Ask a research question about Type 2 Diabetes Mellitus. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

0
Mappings
0
Definitions
0
Inheritance
5
Pathophysiology
0
Histopathology
10
Phenotypes
9
Pathograph
4
Genes
6
Treatments
0
Subtypes
0
Differentials
4
Datasets
0
Trials
5
Models
6
References
2
Deep Research
C

Comorbidities

Atopic Dermatitis <-> Type 2 Diabetes Mellitus
Disease B A_BEFORE_B CANDIDATE
Type 2 Diabetes Mellitus <-> Union of Lichen Simplex Chronicus, Prurigo Nodularis
Disease A A_BEFORE_B CANDIDATE
⚙

Pathophysiology

5
Insulin Resistance
Peripheral tissues (muscle, liver, adipose) become resistant to insulin action, requiring higher insulin levels to maintain glucose homeostasis. This leads to compensatory hyperinsulinemia and eventually beta cell exhaustion.
Hepatocyte link Skeletal Muscle Cell link Adipocyte link
PPARG link
Insulin Signaling link
Downstream
Beta Cell Dysfunction Sustained insulin resistance increases compensatory beta-cell insulin demand, contributing to eventual beta-cell failure.
Hepatic Glucose Overproduction Hepatic insulin resistance reduces insulin-mediated suppression of liver glucose production.
Show evidence (4 references)
PMID:12231074 SUPPORT
"Insulin resistance is caused by the decreased ability of peripheral target tissues (especially muscle) to respond properly to normal circulating concentrations of insulin."
This establishes that skeletal muscle is a key site of insulin resistance in type 2 diabetes, with impaired response to normal insulin levels.
PMID:12231074 SUPPORT
"These alterations in glucose transport activity are likely the result of dysregulation of intramyocellular fatty acid metabolism, whereby fatty acids cause insulin resistance by activation of a serine kinase cascade, leading to decreased insulin-stimulated insulin receptor substrate (IRS)-1..."
This describes the molecular mechanism of insulin resistance involving fatty acid-induced serine kinase activation that impairs insulin receptor signaling through IRS-1 and PI3K.
PMID:29939616 SUPPORT
"Insulin resistance impairs glucose disposal, resulting in a compensatory increase in beta-cell insulin production and hyperinsulinemia."
This confirms that insulin resistance leads to compensatory hyperinsulinemia as beta cells attempt to overcome impaired glucose disposal in peripheral tissues.
+ 1 more reference
Beta Cell Dysfunction
Progressive loss of pancreatic beta cell function and mass leads to inadequate insulin secretion relative to insulin demand. Beta cell failure is the key determinant of disease progression.
Pancreatic Beta Cell link
KCNJ11 link SLC30A8 link
Insulin Secretion link
Downstream
Hyperglycemia Insufficient beta-cell insulin secretion limits glucose control and drives hyperglycemia.
Show evidence (6 references)
PMID:37035220 SUPPORT
"Insulin resistance and pancreatic β-cell dysfunction are major pathological mechanisms implicated in the development and progression of type 2 diabetes (T2D)."
This establishes beta cell dysfunction as a core pathological mechanism in type 2 diabetes development alongside insulin resistance.
PMID:37035220 SUPPORT
"Predominant markers of inflammation such as C-reactive protein, tumor necrosis factor alpha, and interleukin-1β are consistently associated with β-cell failure in preclinical models and in people with T2D."
This demonstrates that inflammatory markers are associated with beta cell failure, indicating inflammation contributes to beta cell dysfunction.
PMID:37035220 SUPPORT
"Similarly, important markers of oxidative stress, such as increased reactive oxygen species and depleted intracellular antioxidants, are consistent with pancreatic β-cell damage in conditions of T2D."
This confirms that oxidative stress, characterized by increased ROS and depleted antioxidants, contributes to pancreatic beta cell damage in type 2 diabetes.
+ 3 more references
Hepatic Glucose Overproduction
Impaired suppression of hepatic gluconeogenesis leads to elevated fasting glucose levels. The liver fails to respond appropriately to insulin signals.
Hepatocyte link
Gluconeogenesis link
Downstream
Hyperglycemia Excess hepatic glucose production contributes directly to impaired glucose homeostasis.
Show evidence (3 references)
PMID:30150719 SUPPORT
"Diabetes is characterized by impaired glucose homeostasis partly due to abnormally elevated hepatic glucose production (HGP)."
This establishes that elevated hepatic glucose production is a key feature of diabetes pathophysiology.
PMID:30150719 SUPPORT
"Metformin exerts its antihyperglycemic action primarily through lowering hepatic glucose production (HGP)."
This confirms that hepatic glucose overproduction is central to diabetes hyperglycemia, as metformin's primary mechanism targets HGP suppression.
PMID:30150719 SUPPORT
"FBP1 catalyzes the irreversible hydrolysis of fructose-1,6-bisphosphate (F-1,6-P2) to fructose-6-phosphate (F6P) and inorganic phosphate (Pi) in the presence of divalent cations. FBP1 is a key rate-controlling enzyme in the gluconeogenic pathway."
This identifies fructose-1,6-bisphosphatase (FBP1) as a key rate-controlling enzyme in hepatic gluconeogenesis, the pathway responsible for glucose overproduction in diabetes.
Mitochondrial Dysfunction and Oxidative Stress
Early-onset mitochondrial dysfunction and pathological reactive oxygen species (ROS) generation occur across multiple metabolic tissues including pancreatic beta cells, skeletal muscle, and adipose tissue. Impaired mitophagy and mitochondrial dynamics contribute to disease progression. Extracellular vesicle-mediated inter-organ miscommunication propagates oxidative damage.
Pancreatic Beta Cell link Skeletal Muscle Cell link
Oxidative Stress Response link Mitophagy link
Show evidence (3 references)
PMID:38338783 SUPPORT
"New evidence suggests that T2D-lean individuals experience early β-cell dysfunction without significant IR. Regardless of the primary event (i.e., IR vs. β-cell dysfunction) that contributes to dysglycemia, significant early-onset oxidative damage and mitochondrial dysfunction in multiple..."
This establishes that mitochondrial dysfunction and oxidative damage occur early and may drive T2D progression regardless of whether insulin resistance or beta cell dysfunction is the primary event.
PMID:38338783 SUPPORT
"Physiological oxidative stress promotes inter-tissue communication, while pathological oxidative stress promotes inter-tissue mis-communication, and new evidence suggests that this is mediated via extracellular vesicles (EVs), including mitochondria containing EVs."
This describes the novel mechanism of extracellular vesicle-mediated oxidative stress propagation between tissues in T2D pathogenesis.
PMID:37035220 SUPPORT
"Similarly, important markers of oxidative stress, such as increased reactive oxygen species and depleted intracellular antioxidants, are consistent with pancreatic β-cell damage in conditions of T2D."
This confirms that oxidative stress characterized by increased ROS and depleted antioxidants contributes to beta cell damage.
Incretin Axis Dysfunction
Impaired incretin hormone signaling, particularly blunted glucose-dependent insulinotropic peptide (GIP) action in beta cells. GLP-1 action is relatively preserved. The incretin effect amplifies insulin secretion in response to oral glucose via cAMP-PKA signaling pathways.
Pancreatic Beta Cell link Enteroendocrine Cell link
TCF7L2 link
cAMP Signaling link Insulin Secretion Regulation link
Downstream
Beta Cell Dysfunction Reduced beta-cell sensitivity to incretins impairs oral-glucose-stimulated insulin secretion.
Show evidence (3 references)
PMID:38831203 PARTIAL
"Dual glucagon like peptide 1 (GLP1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists are among the new pharmacological strategies recently developed to address this challenge."
This establishes the importance of the GLP-1/GIP incretin axis in T2D pathophysiology and its targeting by dual agonist therapies.
PMID:38831203 PARTIAL
"Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity."
This demonstrates the clinical relevance of incretin axis dysfunction by showing dual GLP-1/GIP agonism is effective for T2D treatment.
PMID:19934000 SUPPORT Human Clinical
"The TCF7L2 variant rs7903146 appears to affect risk of type 2 diabetes, at least in part, by modifying the effect of incretins on insulin secretion."
Supports TCF7L2 as a genetic contributor to incretin-axis effects on insulin secretion in humans.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Type 2 Diabetes Mellitus Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Endocrine 1
Hyperinsulinemia FREQUENT Hyperinsulinemia (HP:0000842)
Compensatory response to insulin resistance
Show evidence (1 reference)
PMID:29939616 SUPPORT
"Insulin resistance impairs glucose disposal, resulting in a compensatory increase in beta-cell insulin production and hyperinsulinemia."
This establishes hyperinsulinemia as a compensatory response to insulin resistance in T2D.
Eye 1
Diabetic Retinopathy OCCASIONAL Retinopathy (HP:0000488)
Long-term microvascular complication
Genitourinary 1
Polyuria FREQUENT Polyuria (HP:0000103)
Show evidence (1 reference)
PMID:9398128 SUPPORT
"Polyuria due to a glucose-induced osmotic diuresis is common in patients with hyperglycemia. This diuresis usually abates when the plasma glucose level approaches its renal threshold."
This describes the mechanism of polyuria in diabetes as glucose-induced osmotic diuresis when plasma glucose exceeds the renal threshold.
Metabolism 3
Hyperglycemia VERY_FREQUENT Hyperglycemia (HP:0003074)
Show evidence (2 references)
PMID:29939616 SUPPORT
"This vicious cycle continues until pancreatic beta-cell activity can no longer adequately meet the insulin demand created by insulin resistance, resulting in hyperglycemia."
This describes how the failure of beta cells to compensate for insulin resistance results in hyperglycemia, the hallmark of type 2 diabetes.
PMID:30150719 SUPPORT
"Diabetes is characterized by impaired glucose homeostasis partly due to abnormally elevated hepatic glucose production (HGP)."
This confirms that hyperglycemia in diabetes results from elevated hepatic glucose production and impaired glucose homeostasis.
Insulin Resistance VERY_FREQUENT Insulin resistance (HP:0000855)
Show evidence (1 reference)
PMID:12231074 SUPPORT
"Insulin resistance is caused by the decreased ability of peripheral target tissues (especially muscle) to respond properly to normal circulating concentrations of insulin."
This establishes insulin resistance as a hallmark feature of T2D pathophysiology.
Impaired Glucose Tolerance VERY_FREQUENT Glucose intolerance (HP:0001952)
Nervous System 2
Polydipsia FREQUENT Polydipsia (HP:0001959)
Show evidence (1 reference)
PMID:9398128 PARTIAL
"Polyuria due to a glucose-induced osmotic diuresis is common in patients with hyperglycemia."
This establishes that polyuria results from glucose-induced osmotic diuresis in hyperglycemia, which in turn leads to polydipsia as a compensatory response to fluid loss.
Peripheral Neuropathy OCCASIONAL Peripheral neuropathy (HP:0009830)
Long-term microvascular complication
Constitutional 1
Fatigue FREQUENT Fatigue (HP:0012378)
Growth 1
Obesity FREQUENT Obesity (HP:0001513)
🧬

Genetic Associations

4
TCF7L2 (Risk Factor)
PPARG (Risk Factor)
KCNJ11 (Risk Factor)
SLC30A8 (Risk Factor)
💊

Treatments

6
Metformin
Action: targeted therapy Ontology label: Targeted Therapy NCIT:C93352
Agent: metformin ↗
First-line oral medication that reduces hepatic glucose production and improves insulin sensitivity.
Lifestyle Modification
Action: dietary intervention MAXO:0000088
Diet and exercise interventions to reduce weight and improve metabolic health.
GLP-1 Receptor Agonists
Action: targeted therapy Ontology label: Targeted Therapy NCIT:C93352
Injectable medications that enhance insulin secretion and promote weight loss.
Show evidence (1 reference)
PMID:38831203 PARTIAL
"Dual glucagon like peptide 1 (GLP1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists are among the new pharmacological strategies recently developed to address this challenge."
This establishes GLP-1/GIP receptor agonists as effective pharmacological strategies for T2D treatment.
SGLT2 Inhibitors
Action: pharmacotherapy MAXO:0000058
Oral medications that increase urinary glucose excretion.
Insulin Therapy
Action: insulin therapy Ontology label: insulin treatment MAXO:0000259
Required when beta cell function declines significantly.
GLP-1/GIP Dual Agonists
Action: targeted therapy Ontology label: Targeted Therapy NCIT:C93352
Tirzepatide and similar agents that activate both GLP-1 and GIP receptors for enhanced glycemic control and weight loss.
Show evidence (1 reference)
PMID:38831203 SUPPORT
"Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity."
This confirms tirzepatide as an authorized dual GLP-1/GIP agonist for T2D and obesity treatment.
🌍

Environmental Factors

3
Sedentary Lifestyle
Major modifiable risk factor
High-Calorie Diet
Contributes to obesity and insulin resistance
Obesity
Primary risk factor for insulin resistance
📊

Related Datasets

4
Metformin treatment effects on gut microbiome in T2D sra:PRJNA361402
Shotgun metagenomics from 40 individuals in a randomized, placebo-controlled, double-blind type 2 diabetes study. Samples at baseline and after 4 months of metformin treatment to assess drug-microbiome interactions.
human gut metagenome WGS n=40
fecal sample
Conditions: type 2 diabetes metformin treatment type 2 diabetes placebo
Nature Communications 2022 - metformin-microbiome interactions
Gut microbiome in urban African type 2 diabetes sra:PRJNA607849
16S rRNA gene sequencing of gut microbiome profiles from type 2 diabetes patients and controls in urban African populations, examining geographic and dietary influences on diabetes-associated microbiome signatures.
human gut metagenome
fecal sample
Conditions: type 2 diabetes healthy controls
Frontiers Cellular Infection Microbiology 2020
Gut microbiota in obese T2DM patients - Pakistani cohort sra:PRJNA554535
16S rRNA sequencing of gut microbiota from 60 Pakistani adults comparing obese individuals with type 2 diabetes to healthy controls. V3-V4 hypervariable regions sequenced.
human gut metagenome n=60
fecal sample
Conditions: obese type 2 diabetes healthy controls
PMID:31809500
Chinese MGWAS of gut microbiome in type 2 diabetes sra:PRJNA422434
Landmark metagenome-wide association study (MGWAS) comparing gut microbial DNA from 345 Chinese individuals. Identified ~60,000 T2D-associated markers and established metagenomic linkage groups.
human gut metagenome WGS n=345
fecal sample
Conditions: type 2 diabetes healthy controls
PMID:23023125
Nature 2012 - first MGWAS of T2D, foundational study
🧮

Computational Models

5
Pancreatic Beta Cell Genome-Scale Metabolic Model GENOME_SCALE_METABOLIC
First comprehensive genome-scale metabolic reconstruction of human pancreatic beta cells, integrating transcriptomic data from healthy and type 2 diabetic islets. The model captures beta cell-specific metabolic pathways and identifies metabolic alterations in T2D including impaired glucose-stimulated insulin secretion mechanisms.
PMID:35276551 ↗
PLOS Computational Biology 2022 - context-specific reconstruction using RNA-seq from healthy and T2D beta cells
Whole-Body Human Metabolic Model for Diabetes GENOME_SCALE_METABOLIC
Multi-organ metabolic model (Harvey/Harvetta) capturing inter-organ metabolic fluxes in diabetes. Models liver, muscle, adipose, and pancreas metabolism with tissue-specific constraints derived from omics data.
Repository ↗ PMID:32472720 ↗ Base model: Recon3D
Predicts diabetes biomarkers and drug effects across multiple organs
PBPK Model for GLP-1 Receptor Agonists PHYSIOLOGICAL
Physiologically-based pharmacokinetic model for GLP-1 receptor agonists (semaglutide, tirzepatide) in T2D patients. Incorporates drug absorption, distribution, and receptor binding kinetics to optimize dosing regimens.
Used in clinical trial design and dose optimization for incretin-based therapies
AGORA2 Gut Microbiome Metabolic Models GENOME_SCALE_METABOLIC
Collection of 7,302 strain-resolved genome-scale metabolic reconstructions of human gut microorganisms. Enables personalized microbiome-host metabolic modeling by integrating with human metabolic models (Recon3D). Captures strain-level variation in SCFA production, bile acid metabolism, and drug biotransformation relevant to T2D.
Repository ↗ PMID:36543475 ↗
Nature Biotechnology 2022 - includes drug metabolism capabilities for 98 drugs; enables community-level FBA with MICOM
MICOM Community Metabolic Model COBRApy GENOME_SCALE_METABOLIC
Metagenome-scale modeling framework for simulating metabolic interactions in the gut microbiota. Integrates dietary constraints and taxon abundances from metagenomic data to predict personalized SCFA production, cross-feeding networks, and metabolic fluxes. Applied to T2D to study dysbiosis effects on butyrate production and glucose-insulin signaling.
PMID:31964767 ↗
mSystems 2020 - enables personalized microbiome metabolic modeling from 16S/metagenomics data
{ }

Source YAML

click to show 
name: Type 2 Diabetes Mellitus
creation_date: '2025-12-18T17:01:35Z'
updated_date: '2026-05-09T17:11:56Z'
category: Complex
parents:
- Metabolic Disease
- Endocrine Disease
disease_term:
  preferred_term: type 2 diabetes mellitus
  term:
    id: MONDO:0005148
    label: type 2 diabetes mellitus
pathophysiology:
- name: Insulin Resistance
  description: >
    Peripheral tissues (muscle, liver, adipose) become resistant to insulin action,
    requiring higher insulin levels to maintain glucose homeostasis. This leads to
    compensatory hyperinsulinemia and eventually beta cell exhaustion.
  genes:
  - preferred_term: PPARG
    term:
      id: hgnc:9236
      label: PPARG
  cell_types:
  - preferred_term: Hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  - preferred_term: Skeletal Muscle Cell
    term:
      id: CL:0000188
      label: cell of skeletal muscle
  - preferred_term: Adipocyte
    term:
      id: CL:0000136
      label: adipocyte
  biological_processes:
  - preferred_term: Insulin Signaling
    term:
      id: GO:0008286
      label: insulin receptor signaling pathway
  evidence:
  - reference: PMID:12231074
    reference_title: "Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus."
    supports: SUPPORT
    snippet: "Insulin resistance is caused by the decreased ability of peripheral target tissues (especially muscle) to respond properly to normal circulating concentrations of insulin."
    explanation: This establishes that skeletal muscle is a key site of insulin resistance in type 2 diabetes, with impaired response to normal insulin levels.
  - reference: PMID:12231074
    reference_title: "Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus."
    supports: SUPPORT
    snippet: "These alterations in glucose transport activity are likely the result of dysregulation of intramyocellular fatty acid metabolism, whereby fatty acids cause insulin resistance by activation of a serine kinase cascade, leading to decreased insulin-stimulated insulin receptor substrate (IRS)-1 tyrosine phosphorylation and decreased IRS-1-associated phosphatidylinositol 3-kinase activity, a required step in insulin-stimulated glucose transport into muscle."
    explanation: This describes the molecular mechanism of insulin resistance involving fatty acid-induced serine kinase activation that impairs insulin receptor signaling through IRS-1 and PI3K.
  - reference: PMID:29939616
    reference_title: "Insulin Resistance."
    supports: SUPPORT
    snippet: "Insulin resistance impairs glucose disposal, resulting in a compensatory increase in beta-cell insulin production and hyperinsulinemia."
    explanation: This confirms that insulin resistance leads to compensatory hyperinsulinemia as beta cells attempt to overcome impaired glucose disposal in peripheral tissues.
  - reference: PMID:28507210
    reference_title: "Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Thiazolidinediones reduce insulin resistance by activating peroxisome proliferator–activated receptor γ, a nuclear receptor regulating glucose and lipid metabolism."
    explanation: Supports PPARG as an insulin-sensitizing nuclear receptor pathway relevant to insulin resistance biology.
  downstream:
  - target: Beta Cell Dysfunction
    description: Sustained insulin resistance increases compensatory beta-cell insulin demand, contributing to eventual beta-cell failure.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Compensatory hyperinsulinemia and beta-cell secretory stress
    evidence:
    - reference: PMID:29939616
      reference_title: "Insulin Resistance."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "This vicious cycle continues until pancreatic beta-cell activity can no longer adequately meet the insulin demand created by insulin resistance, resulting in hyperglycemia."
      explanation: Directly supports progression from insulin-resistance-driven insulin demand to beta-cell failure.
  - target: Hepatic Glucose Overproduction
    description: Hepatic insulin resistance reduces insulin-mediated suppression of liver glucose production.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32872570
      reference_title: "Pathophysiology of Type 2 Diabetes Mellitus."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "IR contributes to increased glucose production in the liver and decreased glucose uptake both in the muscle, liver and adipose tissue."
      explanation: Supports insulin resistance as a cause of increased hepatic glucose production.
- name: Beta Cell Dysfunction
  description: >
    Progressive loss of pancreatic beta cell function and mass leads to inadequate
    insulin secretion relative to insulin demand. Beta cell failure is the key
    determinant of disease progression.
  genes:
  - preferred_term: KCNJ11
    term:
      id: hgnc:6257
      label: KCNJ11
  - preferred_term: SLC30A8
    term:
      id: hgnc:20303
      label: SLC30A8
  cell_types:
  - preferred_term: Pancreatic Beta Cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: Insulin Secretion
    term:
      id: GO:0030073
      label: insulin secretion
  evidence:
  - reference: PMID:37035220
    reference_title: "Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress."
    supports: SUPPORT
    snippet: "Insulin resistance and pancreatic β-cell dysfunction are major pathological mechanisms implicated in the development and progression of type 2 diabetes (T2D)."
    explanation: This establishes beta cell dysfunction as a core pathological mechanism in type 2 diabetes development alongside insulin resistance.
  - reference: PMID:37035220
    reference_title: "Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress."
    supports: SUPPORT
    snippet: "Predominant markers of inflammation such as C-reactive protein, tumor necrosis factor alpha, and interleukin-1β are consistently associated with β-cell failure in preclinical models and in people with T2D."
    explanation: This demonstrates that inflammatory markers are associated with beta cell failure, indicating inflammation contributes to beta cell dysfunction.
  - reference: PMID:37035220
    reference_title: "Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress."
    supports: SUPPORT
    snippet: "Similarly, important markers of oxidative stress, such as increased reactive oxygen species and depleted intracellular antioxidants, are consistent with pancreatic β-cell damage in conditions of T2D."
    explanation: This confirms that oxidative stress, characterized by increased ROS and depleted antioxidants, contributes to pancreatic beta cell damage in type 2 diabetes.
  - reference: PMID:29939616
    reference_title: "Insulin Resistance."
    supports: SUPPORT
    snippet: "This vicious cycle continues until pancreatic beta-cell activity can no longer adequately meet the insulin demand created by insulin resistance, resulting in hyperglycemia."
    explanation: This describes the progression from compensatory beta cell hyperfunction to beta cell exhaustion and failure, leading to hyperglycemia.
  - reference: PMID:29931562
    reference_title: "Monogenic Diabetes in Children and Adolescents: Recognition and Treatment Options."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The ABCC8 and KCNJ11 genes encode the sulfonylurea receptor 1 (SUR1) and inward rectifier potassium channel Kir6 (Kir6.2) subunits of the ATP-sensitive potassium (KATP) channel in the pancreatic beta cell, regulating insulin secretion."
    explanation: Supports KCNJ11 as a pancreatic beta-cell KATP-channel gene that regulates insulin secretion.
  - reference: PMID:17463248
    reference_title: "A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SLC30A8 transports zinc from the cytoplasm into insulin secretory vesicles (20, 21), where insulin is stored as a hexamer bound with two Zn2+ ions before secretion (22). Variation in SLC30A8 may affect zinc accumulation in insulin granules, affecting insulin stability, storage, or secretion."
    explanation: Links SLC30A8 to beta-cell insulin granule biology and T2D-associated variation affecting insulin storage or secretion.
  downstream:
  - target: Hyperglycemia
    description: Insufficient beta-cell insulin secretion limits glucose control and drives hyperglycemia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32872570
      reference_title: "Pathophysiology of Type 2 Diabetes Mellitus."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "In the case of β-cell dysfunction, insulin secretion is reduced, limiting the body’s capacity to maintain physiological glucose levels."
      explanation: Supports beta-cell dysfunction as a direct cause of impaired glucose homeostasis.
- name: Hepatic Glucose Overproduction
  description: >
    Impaired suppression of hepatic gluconeogenesis leads to elevated fasting
    glucose levels. The liver fails to respond appropriately to insulin signals.
  cell_types:
  - preferred_term: Hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: Gluconeogenesis
    term:
      id: GO:0006094
      label: gluconeogenesis
  evidence:
  - reference: PMID:30150719
    reference_title: "Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase."
    supports: SUPPORT
    snippet: "Diabetes is characterized by impaired glucose homeostasis partly due to abnormally elevated hepatic glucose production (HGP)."
    explanation: This establishes that elevated hepatic glucose production is a key feature of diabetes pathophysiology.
  - reference: PMID:30150719
    reference_title: "Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase."
    supports: SUPPORT
    snippet: "Metformin exerts its antihyperglycemic action primarily through lowering hepatic glucose production (HGP)."
    explanation: This confirms that hepatic glucose overproduction is central to diabetes hyperglycemia, as metformin's primary mechanism targets HGP suppression.
  - reference: PMID:30150719
    reference_title: "Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase."
    supports: SUPPORT
    snippet: "FBP1 catalyzes the irreversible hydrolysis of fructose-1,6-bisphosphate (F-1,6-P2) to fructose-6-phosphate (F6P) and inorganic phosphate (Pi) in the presence of divalent cations. FBP1 is a key rate-controlling enzyme in the gluconeogenic pathway."
    explanation: This identifies fructose-1,6-bisphosphatase (FBP1) as a key rate-controlling enzyme in hepatic gluconeogenesis, the pathway responsible for glucose overproduction in diabetes.
  downstream:
  - target: Hyperglycemia
    description: Excess hepatic glucose production contributes directly to impaired glucose homeostasis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30150719
      reference_title: "Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Diabetes is characterized by impaired glucose homeostasis partly due to abnormally elevated hepatic glucose production (HGP)."
      explanation: Supports hepatic glucose overproduction as a contributor to diabetes-associated hyperglycemia.
- name: Mitochondrial Dysfunction and Oxidative Stress
  description: >
    Early-onset mitochondrial dysfunction and pathological reactive oxygen species
    (ROS) generation occur across multiple metabolic tissues including pancreatic
    beta cells, skeletal muscle, and adipose tissue. Impaired mitophagy and
    mitochondrial dynamics contribute to disease progression. Extracellular
    vesicle-mediated inter-organ miscommunication propagates oxidative damage.
  cell_types:
  - preferred_term: Pancreatic Beta Cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  - preferred_term: Skeletal Muscle Cell
    term:
      id: CL:0000188
      label: cell of skeletal muscle
  biological_processes:
  - preferred_term: Oxidative Stress Response
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: Mitophagy
    term:
      id: GO:0000422
      label: autophagy of mitochondrion
  evidence:
  - reference: PMID:38338783
    reference_title: "Mitochondrial Dysfunction, Oxidative Stress, and Inter-Organ Miscommunications in T2D Progression."
    supports: SUPPORT
    snippet: "New evidence suggests that T2D-lean individuals experience early β-cell dysfunction without significant IR. Regardless of the primary event (i.e., IR vs. β-cell dysfunction) that contributes to dysglycemia, significant early-onset oxidative damage and mitochondrial dysfunction in multiple metabolic tissues may be a driver of T2D onset and progression."
    explanation: This establishes that mitochondrial dysfunction and oxidative damage occur early and may drive T2D progression regardless of whether insulin resistance or beta cell dysfunction is the primary event.
  - reference: PMID:38338783
    reference_title: "Mitochondrial Dysfunction, Oxidative Stress, and Inter-Organ Miscommunications in T2D Progression."
    supports: SUPPORT
    snippet: "Physiological oxidative stress promotes inter-tissue communication, while pathological oxidative stress promotes inter-tissue mis-communication, and new evidence suggests that this is mediated via extracellular vesicles (EVs), including mitochondria containing EVs."
    explanation: This describes the novel mechanism of extracellular vesicle-mediated oxidative stress propagation between tissues in T2D pathogenesis.
  - reference: PMID:37035220
    reference_title: "Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress."
    supports: SUPPORT
    snippet: "Similarly, important markers of oxidative stress, such as increased reactive oxygen species and depleted intracellular antioxidants, are consistent with pancreatic β-cell damage in conditions of T2D."
    explanation: This confirms that oxidative stress characterized by increased ROS and depleted antioxidants contributes to beta cell damage.
- name: Incretin Axis Dysfunction
  description: >
    Impaired incretin hormone signaling, particularly blunted glucose-dependent
    insulinotropic peptide (GIP) action in beta cells. GLP-1 action is relatively
    preserved. The incretin effect amplifies insulin secretion in response to
    oral glucose via cAMP-PKA signaling pathways.
  genes:
  - preferred_term: TCF7L2
    term:
      id: hgnc:11641
      label: TCF7L2
  cell_types:
  - preferred_term: Pancreatic Beta Cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  - preferred_term: Enteroendocrine Cell
    term:
      id: CL:0000164
      label: enteroendocrine cell
  biological_processes:
  - preferred_term: cAMP Signaling
    term:
      id: GO:0141156
      label: cAMP/PKA signal transduction
  - preferred_term: Insulin Secretion Regulation
    term:
      id: GO:0050796
      label: regulation of insulin secretion
  evidence:
  - reference: PMID:38831203
    reference_title: "GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes."
    supports: PARTIAL
    snippet: "Dual glucagon like peptide 1 (GLP1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists are among the new pharmacological strategies recently developed to address this challenge."
    explanation: This establishes the importance of the GLP-1/GIP incretin axis in T2D pathophysiology and its targeting by dual agonist therapies.
  - reference: PMID:38831203
    reference_title: "GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes."
    supports: PARTIAL
    snippet: "Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity."
    explanation: This demonstrates the clinical relevance of incretin axis dysfunction by showing dual GLP-1/GIP agonism is effective for T2D treatment.
  - reference: PMID:19934000
    reference_title: "TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The TCF7L2 variant rs7903146 appears to affect risk of type 2 diabetes, at least in part, by modifying the effect of incretins on insulin secretion."
    explanation: Supports TCF7L2 as a genetic contributor to incretin-axis effects on insulin secretion in humans.
  downstream:
  - target: Beta Cell Dysfunction
    description: Reduced beta-cell sensitivity to incretins impairs oral-glucose-stimulated insulin secretion.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19934000
      reference_title: "TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This is not due to reduced secretion of GLP-1 and GIP but rather due to the effect of TCF7L2 on the sensitivity of the beta-cell to incretins."
      explanation: Directly supports a TCF7L2-associated incretin-sensitivity defect at the beta cell.
phenotypes:
- name: Hyperglycemia
  category: Metabolic
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Hyperglycemia
    term:
      id: HP:0003074
      label: Hyperglycemia
  evidence:
  - reference: PMID:29939616
    reference_title: "Insulin Resistance."
    supports: SUPPORT
    snippet: "This vicious cycle continues until pancreatic beta-cell activity can no longer adequately meet the insulin demand created by insulin resistance, resulting in hyperglycemia."
    explanation: This describes how the failure of beta cells to compensate for insulin resistance results in hyperglycemia, the hallmark of type 2 diabetes.
  - reference: PMID:30150719
    reference_title: "Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase."
    supports: SUPPORT
    snippet: "Diabetes is characterized by impaired glucose homeostasis partly due to abnormally elevated hepatic glucose production (HGP)."
    explanation: This confirms that hyperglycemia in diabetes results from elevated hepatic glucose production and impaired glucose homeostasis.
- name: Polydipsia
  category: Systemic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Polydipsia
    term:
      id: HP:0001959
      label: Polydipsia
  evidence:
  - reference: PMID:9398128
    reference_title: "Factors contributing to the degree of polyuria in a patient with poorly controlled diabetes mellitus."
    supports: PARTIAL
    snippet: "Polyuria due to a glucose-induced osmotic diuresis is common in patients with hyperglycemia."
    explanation: This establishes that polyuria results from glucose-induced osmotic diuresis in hyperglycemia, which in turn leads to polydipsia as a compensatory response to fluid loss.
- name: Polyuria
  category: Renal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Polyuria
    term:
      id: HP:0000103
      label: Polyuria
  evidence:
  - reference: PMID:9398128
    reference_title: "Factors contributing to the degree of polyuria in a patient with poorly controlled diabetes mellitus."
    supports: SUPPORT
    snippet: "Polyuria due to a glucose-induced osmotic diuresis is common in patients with hyperglycemia. This diuresis usually abates when the plasma glucose level approaches its renal threshold."
    explanation: This describes the mechanism of polyuria in diabetes as glucose-induced osmotic diuresis when plasma glucose exceeds the renal threshold.
- name: Obesity
  category: Metabolic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
- name: Fatigue
  category: Systemic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- name: Insulin Resistance
  category: Metabolic
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Insulin Resistance
    term:
      id: HP:0000855
      label: Insulin resistance
  evidence:
  - reference: PMID:12231074
    reference_title: "Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus."
    supports: SUPPORT
    snippet: "Insulin resistance is caused by the decreased ability of peripheral target tissues (especially muscle) to respond properly to normal circulating concentrations of insulin."
    explanation: This establishes insulin resistance as a hallmark feature of T2D pathophysiology.
- name: Impaired Glucose Tolerance
  category: Metabolic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Impaired Glucose Tolerance
    term:
      id: HP:0001952
      label: Glucose intolerance
- name: Hyperinsulinemia
  category: Metabolic
  frequency: FREQUENT
  notes: Compensatory response to insulin resistance
  phenotype_term:
    preferred_term: Hyperinsulinemia
    term:
      id: HP:0000842
      label: Hyperinsulinemia
  evidence:
  - reference: PMID:29939616
    reference_title: "Insulin Resistance."
    supports: SUPPORT
    snippet: "Insulin resistance impairs glucose disposal, resulting in a compensatory increase in beta-cell insulin production and hyperinsulinemia."
    explanation: This establishes hyperinsulinemia as a compensatory response to insulin resistance in T2D.
- name: Diabetic Retinopathy
  category: Ophthalmologic
  frequency: OCCASIONAL
  notes: Long-term microvascular complication
  phenotype_term:
    preferred_term: Retinopathy
    term:
      id: HP:0000488
      label: Retinopathy
- name: Peripheral Neuropathy
  category: Neurological
  frequency: OCCASIONAL
  notes: Long-term microvascular complication
  phenotype_term:
    preferred_term: Peripheral Neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
genetic:
- name: TCF7L2
  gene_term:
    preferred_term: TCF7L2
    term:
      id: hgnc:11641
      label: TCF7L2
  association: Risk Factor
- name: PPARG
  gene_term:
    preferred_term: PPARG
    term:
      id: hgnc:9236
      label: PPARG
  association: Risk Factor
- name: KCNJ11
  gene_term:
    preferred_term: KCNJ11
    term:
      id: hgnc:6257
      label: KCNJ11
  association: Risk Factor
- name: SLC30A8
  gene_term:
    preferred_term: SLC30A8
    term:
      id: hgnc:20303
      label: SLC30A8
  association: Risk Factor
environmental:
- name: Sedentary Lifestyle
  notes: Major modifiable risk factor
- name: High-Calorie Diet
  notes: Contributes to obesity and insulin resistance
- name: Obesity
  notes: Primary risk factor for insulin resistance
treatments:
- name: Metformin
  description: First-line oral medication that reduces hepatic glucose production and improves insulin sensitivity.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: metformin
      term:
        id: CHEBI:6801
        label: metformin
- name: Lifestyle Modification
  description: Diet and exercise interventions to reduce weight and improve metabolic health.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
- name: GLP-1 Receptor Agonists
  description: Injectable medications that enhance insulin secretion and promote weight loss.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
  evidence:
  - reference: PMID:38831203
    reference_title: "GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes."
    supports: PARTIAL
    snippet: "Dual glucagon like peptide 1 (GLP1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists are among the new pharmacological strategies recently developed to address this challenge."
    explanation: This establishes GLP-1/GIP receptor agonists as effective pharmacological strategies for T2D treatment.
- name: SGLT2 Inhibitors
  description: Oral medications that increase urinary glucose excretion.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Insulin Therapy
  description: Required when beta cell function declines significantly.
  treatment_term:
    preferred_term: insulin therapy
    term:
      id: MAXO:0000259
      label: insulin treatment
- name: GLP-1/GIP Dual Agonists
  description: Tirzepatide and similar agents that activate both GLP-1 and GIP receptors for enhanced glycemic control and weight loss.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
  evidence:
  - reference: PMID:38831203
    reference_title: "GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes."
    supports: SUPPORT
    snippet: "Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity."
    explanation: This confirms tirzepatide as an authorized dual GLP-1/GIP agonist for T2D and obesity treatment.
datasets:
# Type 2 Diabetes Gut Microbiome Studies

- accession: sra:PRJNA361402
  title: Metformin treatment effects on gut microbiome in T2D
  description: >-
    Shotgun metagenomics from 40 individuals in a randomized, placebo-controlled,
    double-blind type 2 diabetes study. Samples at baseline and after 4 months
    of metformin treatment to assess drug-microbiome interactions.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  data_type: WGS
  sample_types:
  - preferred_term: fecal sample
    term:
      id: UBERON:0001988
      label: feces
    tissue_term:
      preferred_term: feces
      term:
        id: UBERON:0001988
        label: feces
  sample_count: 40
  conditions:
  - type 2 diabetes metformin treatment
  - type 2 diabetes placebo
  notes: Nature Communications 2022 - metformin-microbiome interactions

- accession: sra:PRJNA607849
  title: Gut microbiome in urban African type 2 diabetes
  description: >-
    16S rRNA gene sequencing of gut microbiome profiles from type 2 diabetes
    patients and controls in urban African populations, examining geographic
    and dietary influences on diabetes-associated microbiome signatures.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  sample_types:
  - preferred_term: fecal sample
    term:
      id: UBERON:0001988
      label: feces
    tissue_term:
      preferred_term: feces
      term:
        id: UBERON:0001988
        label: feces
  conditions:
  - type 2 diabetes
  - healthy controls
  notes: Frontiers Cellular Infection Microbiology 2020

- accession: sra:PRJNA554535
  title: Gut microbiota in obese T2DM patients - Pakistani cohort
  description: >-
    16S rRNA sequencing of gut microbiota from 60 Pakistani adults comparing
    obese individuals with type 2 diabetes to healthy controls. V3-V4
    hypervariable regions sequenced.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  sample_types:
  - preferred_term: fecal sample
    term:
      id: UBERON:0001988
      label: feces
    tissue_term:
      preferred_term: feces
      term:
        id: UBERON:0001988
        label: feces
  sample_count: 60
  conditions:
  - obese type 2 diabetes
  - healthy controls
  publication: PMID:31809500

- accession: sra:PRJNA422434
  title: Chinese MGWAS of gut microbiome in type 2 diabetes
  description: >-
    Landmark metagenome-wide association study (MGWAS) comparing gut microbial
    DNA from 345 Chinese individuals. Identified ~60,000 T2D-associated markers
    and established metagenomic linkage groups.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  data_type: WGS
  sample_types:
  - preferred_term: fecal sample
    term:
      id: UBERON:0001988
      label: feces
    tissue_term:
      preferred_term: feces
      term:
        id: UBERON:0001988
        label: feces
  sample_count: 345
  conditions:
  - type 2 diabetes
  - healthy controls
  publication: PMID:23023125
  notes: Nature 2012 - first MGWAS of T2D, foundational study
computational_models:
- name: Pancreatic Beta Cell Genome-Scale Metabolic Model
  description: >
    First comprehensive genome-scale metabolic reconstruction of human pancreatic
    beta cells,
    integrating transcriptomic data from healthy and type 2 diabetic islets. The model
    captures
    beta cell-specific metabolic pathways and identifies metabolic alterations in
    T2D including
    impaired glucose-stimulated insulin secretion mechanisms.
  model_type: GENOME_SCALE_METABOLIC
  publication: PMID:35276551
  notes: PLOS Computational Biology 2022 - context-specific reconstruction using RNA-seq from healthy and T2D beta cells
- name: Whole-Body Human Metabolic Model for Diabetes
  description: >
    Multi-organ metabolic model (Harvey/Harvetta) capturing inter-organ metabolic
    fluxes in
    diabetes. Models liver, muscle, adipose, and pancreas metabolism with tissue-specific
    constraints derived from omics data.
  model_type: GENOME_SCALE_METABOLIC
  base_model: Recon3D
  repository_url: https://www.vmh.life/
  publication: PMID:32472720
  notes: Predicts diabetes biomarkers and drug effects across multiple organs
- name: PBPK Model for GLP-1 Receptor Agonists
  description: >
    Physiologically-based pharmacokinetic model for GLP-1 receptor agonists (semaglutide,
    tirzepatide) in T2D patients. Incorporates drug absorption, distribution, and
    receptor
    binding kinetics to optimize dosing regimens.
  model_type: PHYSIOLOGICAL
  notes: Used in clinical trial design and dose optimization for incretin-based therapies
- name: AGORA2 Gut Microbiome Metabolic Models
  description: >
    Collection of 7,302 strain-resolved genome-scale metabolic reconstructions of
    human
    gut microorganisms. Enables personalized microbiome-host metabolic modeling by
    integrating with human metabolic models (Recon3D). Captures strain-level variation
    in SCFA production, bile acid metabolism, and drug biotransformation relevant
    to T2D.
  model_type: GENOME_SCALE_METABOLIC
  repository_url: https://www.vmh.life/
  publication: PMID:36543475
  notes: Nature Biotechnology 2022 - includes drug metabolism capabilities for 98 drugs; enables community-level FBA with MICOM
- name: MICOM Community Metabolic Model
  description: >
    Metagenome-scale modeling framework for simulating metabolic interactions in the
    gut microbiota. Integrates dietary constraints and taxon abundances from metagenomic
    data to predict personalized SCFA production, cross-feeding networks, and metabolic
    fluxes. Applied to T2D to study dysbiosis effects on butyrate production and
    glucose-insulin signaling.
  model_type: GENOME_SCALE_METABOLIC
  model_software: COBRApy
  publication: PMID:31964767
  notes: mSystems 2020 - enables personalized microbiome metabolic modeling from 16S/metagenomics data
references:
- reference: DOI:10.1007/s00592-024-02300-6
  title: 'GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes'
  findings: []
- reference: DOI:10.1007/s43152-024-00056-3
  title: Cellular and Molecular Mechanisms of Insulin Resistance
  findings: []
- reference: DOI:10.1038/s42255-024-01140-6
  title: Genetic architecture of oral glucose-stimulated insulin release provides biological insights into type 2 diabetes aetiology
  findings: []
- reference: DOI:10.3390/ijms25031504
  title: Mitochondrial Dysfunction, Oxidative Stress, and Inter-Organ Miscommunications in T2D Progression
  findings: []
- reference: DOI:10.3390/ijms26031094
  title: 'Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications'
  findings: []
- reference: DOI:10.3390/nu17162708
  title: Type 2 Diabetes and the Multifaceted Gut-X Axes
  findings: []
📚

References & Deep Research

References

6
DOI:10.1007/s00592-024-02300-6
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes
No top-level findings curated for this source.
DOI:10.1007/s43152-024-00056-3
Cellular and Molecular Mechanisms of Insulin Resistance
No top-level findings curated for this source.
DOI:10.1038/s42255-024-01140-6
Genetic architecture of oral glucose-stimulated insulin release provides biological insights into type 2 diabetes aetiology
No top-level findings curated for this source.
DOI:10.3390/ijms25031504
Mitochondrial Dysfunction, Oxidative Stress, and Inter-Organ Miscommunications in T2D Progression
No top-level findings curated for this source.
DOI:10.3390/ijms26031094
Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications
No top-level findings curated for this source.
DOI:10.3390/nu17162708
Type 2 Diabetes and the Multifaceted Gut-X Axes
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Type 2 Diabetes Mellitus
  • Category: Complex
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 29

Key Pathophysiology Nodes

  • Insulin Resistance
  • Beta Cell Dysfunction
  • Hepatic Glucose Overproduction
  • Mitochondrial Dysfunction and Oxidative Stress
  • Incretin Axis Dysfunction
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1007/s00592-024-02300-6
  • DOI:10.1007/s43152-024-00056-3
  • DOI:10.1038/s42255-024-01140-6
  • DOI:10.3390/ijms25031504
  • DOI:10.3390/ijms26031094
  • DOI:10.3390/nu17162708
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 16 citations 2025-12-17T18:38:21.178177

Disease Pathophysiology Research Report

Target Disease - Disease Name: Type 2 Diabetes Mellitus (T2DM) - MONDO ID: MONDO:0005148 - Category: Complex

Pathophysiology description (current understanding, 2023–2024 focus) T2DM arises from the convergence of peripheral insulin resistance (IR) in liver, skeletal muscle, and adipose tissue with progressive pancreatic β-cell dysfunction. IR is driven by intracellular lipid intermediates (diacylglycerols, ceramides) that activate protein kinase C isoforms and promote inhibitory serine phosphorylation of IRS proteins, blunting PI3K–AKT signaling in insulin-responsive tissues, together with inflammation, adipokine imbalance, ER stress, and mitochondrial dysfunction (reviewed mechanistically by Chandrasekaran & Weiskirchen 2024; journal page provides overview of INSR/IRS/PI3K/AKT and mTOR/S6K feedback nodes; https://doi.org/10.1007/s43152-024-00056-3, Feb 2024) (chandrasekaran2024cellularandmolecular pages 1-2). β-cell failure reflects glucolipotoxic stress that perturbs ER proteostasis (UPR activation and proinsulin misfolding), damages mitochondria, alters redox signaling, and can culminate in identity loss/dedifferentiation; islet amyloid polypeptide (IAPP) deposition correlates with β-cell loss in human T2DM (review synthesis 2025 with 2023–2024 literature integration; https://doi.org/10.3390/ijms26031094) (młynarska2025type2diabetes pages 16-18). Cross-tissue mitochondrial dysfunction and pathological ROS occur early in muscle, adipose, and islets and propagate via extracellular vesicle–mediated signals, disturbing mitophagy and organelle dynamics (https://doi.org/10.3390/ijms25031504, Jan 2024) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).

Incretin biology is central to gut–islet crosstalk: GLP-1 action is relatively preserved whereas GIP action is often blunted in T2DM; dual GLP-1/GIP agonism (e.g., tirzepatide) leverages cAMP–PKA signaling to amplify glucose-dependent insulin secretion, enhance β-cell survival, and improve weight and cardiometabolic endpoints (Acta Diabetologica 2024; https://doi.org/10.1007/s00592-024-02300-6, Jun 2024) (ciardullo2024glp1gipreceptorcoagonists pages 1-2). Large-scale human genetics and integrative omics now map effector genes and pathways controlling β-cell function during oral glucose challenges; a 2024 Nature Metabolism GWAS meta-analysis of multiple OGTT-derived β-cell indices identified 55 signals at 44 loci and nominated effector genes (e.g., ACSL1, FAM46C) that modulate insulin secretion in β-cell models (https://doi.org/10.1038/s42255-024-01140-6, Oct 2024) (madsen2024geneticarchitectureof pages 1-2). The gut–liver–pancreas axis (dysbiosis, permeability, LPS/TLR4 activation; SCFA and bile-acid signaling) contributes to systemic inflammation, IR, and β-cell stress, providing mechanistic rationale for microbiome-targeted strategies (Nutrients 2025 synthesis of 2015–2024 evidence; https://doi.org/10.3390/nu17162708) (guo2025type2diabetes pages 4-5).

Mechanism Key molecules/genes (HGNC) Cell types (CL IDs) Tissues (UBERON IDs) Representative GO processes/components Supporting evidence (context IDs)
Peripheral insulin resistance: lipid intermediates (DAG/ceramides) → PKC activation; IRS serine phosphorylation impairing PI3K/AKT signaling PRKCQ, IRS1; lipid intermediates: DAG, CER Skeletal muscle cell (CL:0000187); Adipocyte (CL:0000136); Hepatocyte (CL:0000182) Skeletal muscle organ (UBERON:0002370); Adipose tissue (UBERON:0000990); Liver (UBERON:0002107) insulin receptor signaling pathway (GO:0008286); protein kinase C signaling (GO:0070528) (chandrasekaran2024cellularandmolecular pages 1-2, młynarska2025type2diabetes pages 16-18)
Mitochondrial dysfunction & oxidative stress with mitophagy and EV-mediated inter-organ crosstalk PINK1, PRKN, SOD2; mitophagy regulators Pancreatic beta cell (CL:0000169); Skeletal muscle cell (CL:0000187) Pancreas (UBERON:0001264); Skeletal muscle organ (UBERON:0002370) mitophagy (GO:0000422); response to oxidative stress (GO:0006979) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2, młynarska2025type2diabetes pages 16-18)
Incretin axis — GLP-1/GIP signaling and therapeutic co-agonism influencing β-cell function and systemic metabolism GLP1R, GIPR Pancreatic beta cell (CL:0000169); Enterocyte/enteroendocrine lineage (CL:0000584) Pancreas (UBERON:0001264); Small intestine (UBERON:0002108) cAMP-mediated signaling (GO:0019933); regulation of insulin secretion (GO:0050796) (ciardullo2024glp1gipreceptorcoagonists pages 1-2, chandrasekaran2024cellularandmolecular pages 1-2)
β-cell genetic effector genes (OGTT-based GWAS) that modulate insulin secretion ACSL1, FAM46C (candidate effector genes from BCF-GWAS) Pancreatic beta cell (CL:0000169) Pancreas (UBERON:0001264) regulation of insulin secretion (GO:0050796); insulin receptor signaling (GO:0008286) (madsen2024geneticarchitectureof pages 1-2, młynarska2025type2diabetes pages 16-18)
Gut–liver–pancreas crosstalk: microbiome metabolites and endotoxin-driven inflammation (SCFAs, bile acids, LPS → TLR4) affecting IR and β-cell health TLR4, FFAR2, FFAR3 Enterocyte (CL:0000584); Hepatocyte (CL:0000182); Pancreatic beta cell (CL:0000169) Small intestine (UBERON:0002108); Liver (UBERON:0002107); Pancreas (UBERON:0001264) LPS-mediated TLR4 signaling (GO:0034142); bile acid receptor signaling pathway (GO:1902653) (guo2025type2diabetes pages 4-5, chandrasekaran2024cellularandmolecular pages 1-2)

Table: Compact ontology-aligned summary mapping five core T2D mechanisms to key genes, cell/tissue ontology IDs, representative GO terms, and supporting contemporary evidence for use in knowledge-base annotation.

Core Pathophysiology - Primary mechanisms - Peripheral insulin resistance via lipid-driven PKC activation and impaired INSR–IRS–PI3K–AKT signaling in muscle, adipose, and liver; aggravated by inflammatory and ER-stress signaling and mTOR/S6K negative feedback (https://doi.org/10.1007/s43152-024-00056-3) (chandrasekaran2024cellularandmolecular pages 1-2). - β-cell ER stress and UPR activation with proinsulin folding load; mitochondrial dysfunction/oxidative stress; progressive loss of β-cell identity; IAPP deposition correlating with β-cell loss (https://doi.org/10.3390/ijms26031094) (młynarska2025type2diabetes pages 16-18). - Early, tissue-spanning mitochondrial dysfunction and ROS that drive inter-organ miscommunication (EVs, disturbed mitophagy) (https://doi.org/10.3390/ijms25031504) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2). - Incretin axis attenuation and pharmacologic rescue with GLP-1/GIP agonism (https://doi.org/10.1007/s00592-024-02300-6) (ciardullo2024glp1gipreceptorcoagonists pages 1-2). - Gut–liver–pancreas crosstalk: endotoxemia (LPS→TLR4), altered SCFAs and bile-acid signaling impair insulin sensitivity and β-cell function (https://doi.org/10.3390/nu17162708) (guo2025type2diabetes pages 4-5).

  • Dysregulated molecular pathways and affected cellular processes
  • Insulin receptor signaling pathway; PKC activation by DAG/ceramides; IRS serine phosphorylation; downstream GLUT4 trafficking defects (https://doi.org/10.1007/s43152-024-00056-3) (chandrasekaran2024cellularandmolecular pages 1-2).
  • ER stress/UPR arms (PERK–eIF2α/ATF4, IRE1–XBP1s, ATF6); proinsulin proteostasis strain; β-cell identity programs (review integration) (https://doi.org/10.3390/ijms26031094) (młynarska2025type2diabetes pages 16-18).
  • Mitochondrial ROS production, impaired mitophagy (PINK1–PRKN), and organelle dynamics affecting GSIS and survival (https://doi.org/10.3390/ijms25031504) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).
  • Incretin receptor (GLP1R, GIPR) cAMP–PKA signaling amplifying GSIS and promoting survival; system-level metabolic actions (https://doi.org/10.1007/s00592-024-02300-6) (ciardullo2024glp1gipreceptorcoagonists pages 1-2).
  • TLR4/NF-κB activation by LPS; reduced SCFA receptor (FFAR2/3) signaling; altered bile-acid (FXR/TGR5) pathways (https://doi.org/10.3390/nu17162708) (guo2025type2diabetes pages 4-5).

Key Molecular Players - Genes/Proteins (HGNC; examples) - INSR, IRS1/2, PIK3R1/PIK3CA, AKT2; PRKCQ (PKC-θ); mTOR/S6K1 (https://doi.org/10.1007/s43152-024-00056-3) (chandrasekaran2024cellularandmolecular pages 1-2). - ER stress/UPR: EIF2AK3 (PERK), ERN1 (IRE1), ATF6; chaperones HSPA5 (BiP/GRP78); TXNIP as stress amplifier (review) (https://doi.org/10.3390/ijms26031094) (młynarska2025type2diabetes pages 16-18). - Mitochondria/mitophagy: PINK1, PRKN; antioxidant SOD2 (https://doi.org/10.3390/ijms25031504) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2). - Incretin axis: GLP1R, GIPR (https://doi.org/10.1007/s00592-024-02300-6) (ciardullo2024glp1gipreceptorcoagonists pages 1-2). - β-cell effector genes: ACSL1, FAM46C from OGTT-based BCF GWAS; functional silencing impacts insulin secretion (https://doi.org/10.1038/s42255-024-01140-6) (madsen2024geneticarchitectureof pages 1-2). - Innate/metabolic sensors: TLR4; SCFA receptors FFAR2/FFAR3 (https://doi.org/10.3390/nu17162708) (guo2025type2diabetes pages 4-5).

  • Chemical entities (CHEBI; examples)

  • Diacylglycerols (DAG), ceramides (CER) as lipotoxic mediators; lipopolysaccharide (LPS); SCFAs (acetate, butyrate); bile acids (class) (mechanisms summarized) (chandrasekaran2024cellularandmolecular pages 1-2, guo2025type2diabetes pages 4-5).

  • Cell types (CL)

  • Skeletal myocyte (CL:0000187), adipocyte (CL:0000136), hepatocyte (CL:0000182), pancreatic β-cell (CL:0000169), enterocyte/enteroendocrine lineage (CL:0000584) (mechanistic mapping) (chandrasekaran2024cellularandmolecular pages 1-2, ciardullo2024glp1gipreceptorcoagonists pages 1-2, guo2025type2diabetes pages 4-5).

  • Anatomical locations (UBERON)

  • Skeletal muscle organ (UBERON:0002370), adipose tissue (UBERON:0000990), liver (UBERON:0002107), pancreas (UBERON:0001264), small intestine (UBERON:0002108) (chandrasekaran2024cellularandmolecular pages 1-2, ciardullo2024glp1gipreceptorcoagonists pages 1-2, guo2025type2diabetes pages 4-5).

Biological Processes (for GO annotation; examples) - Insulin receptor signaling pathway (GO:0008286) and GLUT4 trafficking defects in IR tissues (mechanism synthesis) (chandrasekaran2024cellularandmolecular pages 1-2). - Protein kinase C signaling (GO:0070528) downstream of DAG/ceramide (chandrasekaran2024cellularandmolecular pages 1-2). - Unfolded protein response (GO:0030968) and ER stress signaling in β-cells (młynarska2025type2diabetes pages 16-18). - Mitophagy (GO:0000422) and response to oxidative stress (GO:0006979) across islets and muscle (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2). - cAMP-mediated signaling (GO:0019933) and regulation of insulin secretion (GO:0050796) by GLP-1/GIP (ciardullo2024glp1gipreceptorcoagonists pages 1-2). - LPS-mediated TLR4 signaling (GO:0034142) and bile-acid receptor signaling pathway (GO:1902653) in gut–liver axis (guo2025type2diabetes pages 4-5).

Cellular Components (where processes occur) - Plasma membrane/lipid rafts: INSR/IRS complex; PKC localization in IR (chandrasekaran2024cellularandmolecular pages 1-2). - Endoplasmic reticulum: proinsulin folding, UPR sensors PERK/IRE1/ATF6 (młynarska2025type2diabetes pages 16-18). - Mitochondria: respiratory chain, ROS generation, mitophagy machinery (PINK1/PRKN) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2). - Endosomes/secretory granules: incretin receptor trafficking; insulin granule exocytosis (ciardullo2024glp1gipreceptorcoagonists pages 1-2). - TLR4 localization at the plasma membrane of enterocytes/hepatocytes/immune cells (guo2025type2diabetes pages 4-5).

Disease Progression (sequence of events) 1) Energy surplus, inactivity, and/or genetic risk promote ectopic lipid accumulation in muscle/liver/adipose; DAG/ceramides activate PKC and inhibit INSR–IRS–PI3K–AKT, producing tissue-specific IR with compensatory hyperinsulinemia (https://doi.org/10.1007/s43152-024-00056-3) (chandrasekaran2024cellularandmolecular pages 1-2). 2) Chronic nutrient load and inflammatory signaling induce ER stress/UPR and mitochondrial dysfunction in β-cells; redox imbalance and defective mitophagy accumulate, impairing GSIS (https://doi.org/10.3390/ijms25031504; https://doi.org/10.3390/ijms26031094) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2, młynarska2025type2diabetes pages 16-18). 3) Progressive β-cell dysfunction (reduced function/mass, dedifferentiation) fails to match IR, unmasking fasting and postprandial hyperglycemia (review synthesis; clinical trajectory) (młynarska2025type2diabetes pages 16-18). 4) Gut dysbiosis and barrier defects worsen systemic inflammation (LPS→TLR4) and metabolic signaling (reduced SCFA and altered bile-acid signaling), aggravating IR and β-cell stress (https://doi.org/10.3390/nu17162708) (guo2025type2diabetes pages 4-5). 5) Incretin defect (blunted GIP) diminishes oral-glucose insulinotropic effect; pharmacologic GLP-1/GIP agonism can restore gut–islet amplification, reduce weight, and improve cardiometabolic profiles (https://doi.org/10.1007/s00592-024-02300-6) (ciardullo2024glp1gipreceptorcoagonists pages 1-2).

Phenotypic Manifestations (selected HP terms) - Hyperglycemia (HP:0003074), Impaired glucose tolerance (HP:0001952), Insulin resistance (HP:0000855), Hyperinsulinemia (HP:0000846), Obesity (HP:0001513). Mechanistically linked to IR and β-cell dysfunction as above (chandrasekaran2024cellularandmolecular pages 1-2, młynarska2025type2diabetes pages 16-18).

Recent developments and latest research (2023–2024 priority) - Archetypes and early β-cell failure: Evidence that lean T2D can present with early β-cell dysfunction without marked IR; across tissues, pathological ROS and mitochondrial dysfunction emerge early and may drive progression; EV-mediated organ crosstalk is implicated (IJMS 2024; https://doi.org/10.3390/ijms25031504) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2). - OGTT-based β-cell function genetics: GWAS meta-analysis of eight OGTT-derived β-cell traits identified 55 signals/44 loci and 92 candidate effectors; ACSL1 and FAM46C validated as regulators of insulin secretion in human β-cell models (Nature Metabolism 2024; https://doi.org/10.1038/s42255-024-01140-6) (madsen2024geneticarchitectureof pages 1-2). - Incretin co-agonism: Dual GLP-1/GIP agonists (tirzepatide) show strong glucose-lowering and weight loss with mechanistic actions on β-cell mass/function and multiorgan metabolism (Acta Diabetologica 2024; https://doi.org/10.1007/s00592-024-02300-6) (ciardullo2024glp1gipreceptorcoagonists pages 1-2). - Systems synthesis of IR mechanisms: Consolidated molecular map of INSR/IRS/PI3K/AKT with lipid-induced PKC activation, mTOR/S6K negative feedback, ER stress, and mitochondrial dysfunction as convergent IR pathways (2024 review; https://doi.org/10.1007/s43152-024-00056-3) (chandrasekaran2024cellularandmolecular pages 1-2). - Gut–X axes: Integrative review outlines gut permeability/endotoxemia, BCAA/SCFA/bile-acid signaling, and neural–endocrine crosstalk linking microbiota to hepatic IR and β-cell function (Nutrients 2025; covers 2015–2024 human/animal data; https://doi.org/10.3390/nu17162708) (guo2025type2diabetes pages 4-5).

Current applications and real-world implementations - Incretin-based therapeutics: GLP-1 receptor agonists and GLP-1/GIP co-agonists used for T2DM and obesity produce glucose-dependent insulinotropic effects, appetite suppression, and cardiometabolic benefit; mechanisms via cAMP–PKA amplifying β-cell exocytosis, anti-apoptosis, and multiorgan actions (https://doi.org/10.1007/s00592-024-02300-6) (ciardullo2024glp1gipreceptorcoagonists pages 1-2). - Mechanism-driven stratification: Genetic variation at GLP1R and β-cell effector genes (e.g., ACSL1, FAM46C) suggests avenues for precision incretin therapy and β-cell–centric target discovery (https://doi.org/10.1038/s42255-024-01140-6) (madsen2024geneticarchitectureof pages 1-2). - Systems targets for IR: Strategies reducing DAG/ceramide load, dampening mTOR/S6K feedback, or alleviating ER/mitochondrial stress align to the consolidated IR map (https://doi.org/10.1007/s43152-024-00056-3) (chandrasekaran2024cellularandmolecular pages 1-2).

Expert opinions and authoritative analysis - Mechanistic IR framework (INSR–IRS–PI3K–AKT; lipid–PKC; mTOR/S6K feedback) remains the cornerstone for interpreting tissue-specific IR and for target selection (Chandrasekaran & Weiskirchen 2024) (chandrasekaran2024cellularandmolecular pages 1-2). - Contemporary view emphasizes mitochondrial dysfunction/ROS and inter-organ miscommunication as early, unifying drivers across patient archetypes, refocusing prevention on mitochondrial quality control and oxidative signaling (Veluthakal et al., 2024) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2). - Incretin co-agonism represents a mechanistically coherent platform therapy addressing both β-cell and whole-body energy balance (Ciardullo et al., 2024) (ciardullo2024glp1gipreceptorcoagonists pages 1-2).

Relevant statistics and data - OGTT β-cell function GWAS: 55 independent associations at 44 loci across eight β-cell indices (~26,000 individuals), nominating 92 candidate effector genes; ACSL1/FAM46C perturbation alters insulin secretion in β-cell models (Nature Metabolism 2024) (madsen2024geneticarchitectureof pages 1-2). - Prediabetes global burden: ~541 million adults; mitochondrial dysfunction and ROS proposed as early drivers (IJMS 2024 synthesis) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).

Ontology-aligned annotations - HGNC: INSR; IRS1/IRS2; PIK3CA/PIK3R1; AKT2; PRKCQ; EIF2AK3 (PERK); ERN1 (IRE1); ATF6; HSPA5; PINK1; PRKN; SOD2; GLP1R; GIPR; ACSL1; FAM46C; TLR4; FFAR2/FFAR3 (chandrasekaran2024cellularandmolecular pages 1-2, młynarska2025type2diabetes pages 16-18, veluthakal2024mitochondrialdysfunctionoxidative pages 1-2, ciardullo2024glp1gipreceptorcoagonists pages 1-2, madsen2024geneticarchitectureof pages 1-2, guo2025type2diabetes pages 4-5). - GO Processes: insulin receptor signaling pathway (GO:0008286); protein kinase C signaling (GO:0070528); unfolded protein response (GO:0030968); response to oxidative stress (GO:0006979); mitophagy (GO:0000422); cAMP-mediated signaling (GO:0019933); regulation of insulin secretion (GO:0050796); LPS-mediated TLR4 signaling (GO:0034142); bile acid receptor signaling pathway (GO:1902653) (chandrasekaran2024cellularandmolecular pages 1-2, młynarska2025type2diabetes pages 16-18, veluthakal2024mitochondrialdysfunctionoxidative pages 1-2, ciardullo2024glp1gipreceptorcoagonists pages 1-2, guo2025type2diabetes pages 4-5). - CL: skeletal muscle cell (CL:0000187); adipocyte (CL:0000136); hepatocyte (CL:0000182); pancreatic β-cell (CL:0000169); enterocyte/enteroendocrine (CL:0000584) (mapped in mechanisms) (chandrasekaran2024cellularandmolecular pages 1-2, ciardullo2024glp1gipreceptorcoagonists pages 1-2, guo2025type2diabetes pages 4-5). - UBERON: skeletal muscle organ (UBERON:0002370); adipose tissue (UBERON:0000990); liver (UBERON:0002107); pancreas (UBERON:0001264); small intestine (UBERON:0002108) (chandrasekaran2024cellularandmolecular pages 1-2, ciardullo2024glp1gipreceptorcoagonists pages 1-2, guo2025type2diabetes pages 4-5). - CHEBI: diacylglycerol (DAG); ceramide; lipopolysaccharide (LPS); acetate; butyrate; bile acids (chandrasekaran2024cellularandmolecular pages 1-2, guo2025type2diabetes pages 4-5). - HP: Hyperglycemia (HP:0003074); Impaired glucose tolerance (HP:0001952); Insulin resistance (HP:0000855); Hyperinsulinemia (HP:0000846); Obesity (HP:0001513) (linked in clinical manifestations) (chandrasekaran2024cellularandmolecular pages 1-2, młynarska2025type2diabetes pages 16-18).

Evidence items (with URLs and publication dates) - Chandrasekaran P, Weiskirchen R. Cellular and molecular mechanisms of insulin resistance. Current Tissue Microenvironment Reports. Feb 2024. https://doi.org/10.1007/s43152-024-00056-3 (chandrasekaran2024cellularandmolecular pages 1-2). - Veluthakal R, et al. Mitochondrial dysfunction, oxidative stress, and inter-organ miscommunications in T2D. IJMS. Jan 2024. https://doi.org/10.3390/ijms25031504 (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2). - Madsen AL, et al. Genetic architecture of OGTT β-cell function and effector genes. Nature Metabolism. Oct 2024. https://doi.org/10.1038/s42255-024-01140-6 (madsen2024geneticarchitectureof pages 1-2). - Ciardullo S, et al. GLP-1–GIP receptor co-agonists in T2D. Acta Diabetologica. Jun 2024. https://doi.org/10.1007/s00592-024-02300-6 (ciardullo2024glp1gipreceptorcoagonists pages 1-2). - Guo H, et al. Type 2 diabetes and the multifaceted Gut–X axes. Nutrients. Aug 2025 (synthesizes 2015–2024 research). https://doi.org/10.3390/nu17162708 (guo2025type2diabetes pages 4-5). - Młynarska E, et al. T2DM: new pathogenetic mechanisms. IJMS. Jan 2025 (integrates 2023–2024 findings). https://doi.org/10.3390/ijms26031094 (młynarska2025type2diabetes pages 16-18).

Therapeutic mechanistic implications - Incretin-based therapies (GLP-1 RAs; GLP-1/GIP co-agonists) target cAMP–PKA amplification of GSIS, β-cell survival, gastric emptying, appetite circuits, and renal/cardiovascular axes—explaining observed HbA1c and weight reductions and CV risk benefits (https://doi.org/10.1007/s00592-024-02300-6) (ciardullo2024glp1gipreceptorcoagonists pages 1-2). - IR pathway targeting: lowering lipid intermediates (DAG/ceramides), relieving mTOR/S6K negative feedback, and reducing ER/mitochondrial stress align with mechanistic maps of IR (https://doi.org/10.1007/s43152-024-00056-3) (chandrasekaran2024cellularandmolecular pages 1-2). - Mitochondrial/oxidative stress interventions and improving mitophagy/MQC are rational to interrupt early cross-tissue drivers of disease (https://doi.org/10.3390/ijms25031504) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).

Limitations Some lines of evidence (e.g., direct human islet amyloid dynamics and detailed UPR arm contributions) are summarized from integrative reviews that compiled 2023–2024 studies; where possible, we prioritized peer-reviewed 2024 primary/large-scale human evidence (madsen2024geneticarchitectureof pages 1-2, chandrasekaran2024cellularandmolecular pages 1-2, ciardullo2024glp1gipreceptorcoagonists pages 1-2). (młynarska2025type2diabetes pages 16-18, veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).

References

  1. (chandrasekaran2024cellularandmolecular pages 1-2): Preethi Chandrasekaran and Ralf Weiskirchen. Cellular and molecular mechanisms of insulin resistance. Current Tissue Microenvironment Reports, pages 1-12, Feb 2024. URL: https://doi.org/10.1007/s43152-024-00056-3, doi:10.1007/s43152-024-00056-3. This article has 72 citations.

  2. (młynarska2025type2diabetes pages 16-18): Ewelina Młynarska, Witold Czarnik, Natasza Dzieża, Weronika Jędraszak, Gabriela Majchrowicz, Filip Prusinowski, Magdalena Stabrawa, Jacek Rysz, and Beata Franczyk. Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications. International Journal of Molecular Sciences, 26:1094, Jan 2025. URL: https://doi.org/10.3390/ijms26031094, doi:10.3390/ijms26031094. This article has 144 citations and is from a poor quality or predatory journal.

  3. (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2): Rajakrishnan Veluthakal, Diana Esparza, Joseph M. Hoolachan, Rekha Balakrishnan, Miwon Ahn, Eunjin Oh, Chathurani S. Jayasena, and Debbie C. Thurmond. Mitochondrial dysfunction, oxidative stress, and inter-organ miscommunications in t2d progression. International Journal of Molecular Sciences, 25:1504, Jan 2024. URL: https://doi.org/10.3390/ijms25031504, doi:10.3390/ijms25031504. This article has 53 citations and is from a poor quality or predatory journal.

  4. (ciardullo2024glp1gipreceptorcoagonists pages 1-2): Stefano Ciardullo, Mario Luca Morieri, Giuseppe Daniele, Teresa Vanessa Fiorentino, Teresa Mezza, Domenico Tricò, Agostino Consoli, Stefano Del Prato, Francesco Giorgino, Salvatore Piro, Anna Solini, and Angelo Avogaro. Glp1-gip receptor co-agonists: a promising evolution in the treatment of type 2 diabetes. Acta Diabetologica, 61:941-950, Jun 2024. URL: https://doi.org/10.1007/s00592-024-02300-6, doi:10.1007/s00592-024-02300-6. This article has 17 citations and is from a peer-reviewed journal.

  5. (madsen2024geneticarchitectureof pages 1-2): A. L. Madsen, S. Bonàs-Guarch, S. Gheibi, R. Prasad, J. Vangipurapu, V. Ahuja, L. R. Cataldo, O. Dwivedi, G. Hatem, G. Atla, M. Guindo-Martínez, A. M. Jørgensen, A. E. Jonsson, I. Miguel-Escalada, S. Hassan, A. Linneberg, Tarunveer S. Ahluwalia, T. Drivsholm, O. Pedersen, T. I. A. Sørensen, A. Astrup, D. Witte, P. Damm, T. D. Clausen, E. Mathiesen, T. H. Pers, R. J. F. Loos, L. Hakaste, M. Fex, N. Grarup, T. Tuomi, M. Laakso, H. Mulder, J. Ferrer, and T. Hansen. Genetic architecture of oral glucose-stimulated insulin release provides biological insights into type 2 diabetes aetiology. Nature Metabolism, 6:1897-1912, Oct 2024. URL: https://doi.org/10.1038/s42255-024-01140-6, doi:10.1038/s42255-024-01140-6. This article has 8 citations and is from a domain leading peer-reviewed journal.

  6. (guo2025type2diabetes pages 4-5): Hezixian Guo, Liyi Pan, Qiuyi Wu, Linhao Wang, Zongjian Huang, Jie Wang, Li Wang, Xiang Fang, Sashuang Dong, Yanhua Zhu, and Zhenlin Liao. Type 2 diabetes and the multifaceted gut-x axes. Nutrients, 17:2708, Aug 2025. URL: https://doi.org/10.3390/nu17162708, doi:10.3390/nu17162708. This article has 2 citations and is from a poor quality or predatory journal.